SCHEMBL892779

SCHEMBL892779

NC(=O)c1cnc(-c2ccccc2)s1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.68
NPC1 O15118 5/20 0.68
RAB9A P51151 5/20 0.68
ALDH1A1 P00352 5/20 0.68
SMN1; SMN2 Q16637 5/20 0.68
HDAC1 Q13547 1/20 0.64
HDAC6 Q9UBN7 1/20 0.64
CYP1A2 P05177 2/20 0.59
NFKB1 P19838 1/20 0.55
PPARG P37231 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
NCOA2 Q15596 1/20 0.55
NCOA1 Q15788 1/20 0.55
NCOA3 Q9Y6Q9 1/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1222603 0.85 ALDH1A1 (0.72) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL27768717 0.85 NPC1 (0.83) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL10848656 0.84 CDC7 (0.61) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL5392323 0.83 CYP3A4 (0.56) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL29548990 0.83 CYP3A4 (0.56) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL31341150 0.83 PTPN11 (0.58) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL6604867 0.83 SMN1; SMN2 (0.69) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL892319 0.83 SMN1; SMN2 (0.49) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL999672 0.83 GSK3B (0.49) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL850828 0.82 NPC1 (0.68) MAPTNPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727546-A2 PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE The Global Alliance for TB Drug Development, Inc. (US) 2026-04-22 EP claimed
EP-4618978-A1 COMPOUNDS, COMPOSITIONS, AND METHODS Tenvie Therapeutics Inc. (US) 2025-09-24 EP claimed
WO-2025019626-A2 PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2025-01-23 WO claimed
WO-2024108147-A1 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2024-05-23 WO claimed
CN-107922374-A New catechol derivatives and the pharmaceutical composition containing it 自体吞噬科学有限公司 2018-04-17 CN claimed
CN-102532123-A Thiazole-5-methanamide compound and preparation method, medicinal composition and application thereof INST MATERIA MEDICA CAMS 2012-07-04 CN claimed
US-20100120798-A1 SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY ASTEX THERAPEUTICS LIMITED (GB) 2010-05-13 US claimed
EP-2125820-A1 SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY Astex Therapeutics Limited (GB) 2009-12-02 EP claimed
WO-2008075110-A1 SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY ASTEX THERAPEUTICS LIMITED (GB) 2008-06-26 WO claimed
EP-4727546-A2 PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE The Global Alliance for TB Drug Development, Inc. (US) 2026-04-22 EP disclosed
EP-4618978-A1 COMPOUNDS, COMPOSITIONS, AND METHODS Tenvie Therapeutics Inc. (US) 2025-09-24 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2025019626-A2 PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2025-01-23 WO disclosed
WO-2024108147-A1 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2024-05-23 WO disclosed
CN-101951774-A Herbicide combinations comprising a herbicide of the class of the diaminos-triazines BAYER CROPSCIENCE AG 2011-01-19 CN disclosed
US-20100120798-A1 SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY ASTEX THERAPEUTICS LIMITED (GB) 2010-05-13 US disclosed
EP-2125820-A1 SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY Astex Therapeutics Limited (GB) 2009-12-02 EP disclosed
WO-2008075110-A1 SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY ASTEX THERAPEUTICS LIMITED (GB) 2008-06-26 WO disclosed
EP-1761502-A1 N-PHENYLPYRAZOLE DERIVATIVES AS PESTICIDES Merial Limited (US) 2007-03-14 EP disclosed
WO-2006000313-A1 N-PHENYLPYRAZOLE DERIVATIVES AS PESTICIDES MERIAL LTD. (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120798-A1 SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY GRK2, GNAO1, PTGER1 MAPT 3976/4885NPC1 457/4885RAB9A 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.